Hello everyone, and welcome to Cinclus Pharma's first quarter 2025 earnings call. I'm Christer Ahlberg, CEO of Cinclus Pharma, and with me today is also our CFO, Maria Engström. We will present the latest developments from the first quarter of 2025 and the upcoming news flow, after which we will be happy to answer any questions you might have. Before we begin, though, I would like to share a quick reminder with our listeners that during today's call, management, Marie and I may make forward-looking statements that involve known and unknown risks, uncertainties, and other important factors beyond the company's control that could cause the company's actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements.
So please note that these forward-looking statements made during this call speak only as of today's date, and the company undertakes no obligation to update them to reflect subsequent events or circumstances, other than to the extent required by law.
With those formalities out of the way.
So let's begin with our lead asset.
Discuss our lead asset Linaprazan glurate. It's actually a PCAB, as you know, a potassium competitive acid blocker.
We have developed this primarily for the treatment of GERD, and Linaprazan represents a new class, the PCAB, which has the potential to replace the current standard treatment.
The PPI, proton pump inhibitors. And we believe that our substance Linaprazan glurate really has the potential to become the best in class. And actually, it represents, I would say, the first application of that innovative mechanism of action. With 25 years of experience, our strategy focuses on the healing of severe patients, enabling us to aim for the specialty pharma commercial focus, which is important in this case. Additionally, it presents the greatest differentiation from the PPIs and the first generation of PCABs. And that gives us a strong competitive position in the future.
And we have also seen that the positive Phase 2 results support our significant achievements, and we have de-risked the Linaprazan glurate program. And we are now progressing towards the Phase 3 study focusing on eGERD. As you know from before, we are backed by strong investors, including life science-focused institutional investors like Trill Impact Ventures, AP4, Linc AB, and Eir Ventures.
And yes, some business updates.
Then, as we have all discussed before, eGERD affects approximately 28 million adults in the US and Europe, including the 10 million with severe eGERD, which is our target population. Despite the availability of PPI therapy, we still see that approximately 10% of the mild patients, more than 30% of the moderate, and over 50% of the severe eGERD patients fail to achieve healing after eight weeks of treatment. In addition to that, we can also say that we see significant relapse from the current treatment, including perhaps the first generation of patients. So there definitely remains a significant unmet medical need and a substantial addressable market still.
And we are currently progressing towards a Phase 3 study. As we have said, we have successfully finalized and completed the Phase 2 evaluation in Europe and also in the US, with close to 250 patients. The results were really, really good. We demonstrated a 93% healing rate among the most severe patients, which is our target population. Actually, we also observed a 100% healing rate in partial responders who had previously been treated with eight weeks of PPI treatment before the study.
We are preparing to initiate the Phase 3 study now in Europe and the US. Returning to that, we will have the top-line results during 2026.
Our current financial visibility suggests that we will have cash throughout the second quarter of 2026, covering the top line results. So, we will have the top-line results before we are running out of cash. In parallel to that, we are also working intensively on the business development activities that have been ongoing.
Also for the first month here. Proceeding to the addressable market, we can observe more details here.
The market in the US and EU demonstrates how substantial it is, with the potential market for Linaprazan glurate among people suffering from the most severe forms of eGERD estimated to be ten million in these regions and 90 million globally. So we can definitely see that we have blockbuster potential here. Just an overview of the global situation.
What you can see is that PCABs are taking over the market from the old APIs and the standard treatment for gastric acid-related diseases in countries where they have been launched. Takeda and the Korean and Chinese manufacturers are increasing licensing, registering, and launching their products in the rest of the world markets, for instance, in Mexico. A PCAB has already secured the third position in the peptic ulcer market within its second year, and it has also achieved a notable price premium over PPIs, which is very interesting to follow. We can see that associations like physicians in India have recently issued broad consensus recommendations for the use of PCABs in managing acid peptic disorders, and at least 11 brands of PCABs have already been launched in the country, with more expected to come. Takeda is focusing on Linaprazan glurate production and strategic launches. On refocusing, I should say focusing on one product in Korea and Brazil, we see that there are more than 30 markets where we can see that PCABs are on sale and confirmed with the launches. We are really seeing activity around the PCAB heating up across the world. And just the latest example is the biggest gastric conference in the world, where we saw the most active PCB schedule ever, with more than 25 PCB-related presentations during those days we were there.
So definitely, PCABs are on the topic now around the world. And we can clearly see here how Linaprazan glurate as a next-generation treatment can be compared both pharmacologically and clinically. Compared to the PPIs and the first generation of PCABs. I mean, such a person. We can see that Linaprazan glurate holds an advantage over the other treatment options with its. I mean, thanks to the program that we have developed, we see faster symptom relief.
We observe the fastest healing and achieve the highest control percentages over a 24-hour period, which is essential for clinically healing the patients. And therefore, we also see very good healing results in half the time compared to the first generation, both to the PPI and the first generation of PCABs.
We also have the ambition of showing superiority, both in achieving healing in half the time and in providing superior daytime and nighttime symptom relief, so we can achieve a best-in-class drug here. That is the ambition we have, and the substance definitely supports this potential. You have that potential. Another important factor in launching a product is the specificity, especially in the EU market, where we see a highly dynamic environment with multiple drugs. What possibilities? I think that is key in a market like this. This diagram shows how eGERD patients currently experience an acute healing phase followed by maintenance treatment before reverting to acute healing treatment again. This means that there is substantial market potential, despite us not being first to market. As long as Linaprazan glurate achieves best-in-class status, which is definitely something we have the possibility to do.
And as an example here, even though we are not the first, we would like to be the best.
Here's an example of the dynamics at play here. You can see in one episode from the first generation, perhaps 25% of patients relapsed within six months on maintenance treatment with that substance. And of course, that will increase over the 12-month period. So definitely, there are different switch possibilities to consider here.
That's the reason why I also think this slide is interesting to look at, because our ambition at Cinclus is to develop a unique next-generation PCAB that meets the medical need and provides the conditions to do exactly what AstraZeneca did when they launched the next generation PPI, Nexium.
In fact, 12 years after the introduction of Losec, or Prilosec, or Omeprazole. In other words, we would like to capture the market following the first generation.
And as you can see, the sales figures show what AstraZeneca managed to achieve. They achieved it in quite a fast period of time. A dynamic market in combination with the best-in-class position is the key to managing to do something like that. And that's the reason why we believe that this is definitely a possibility. Also important is the IP protection, as Cinclus Pharma has robust patent protection for Linaprazan glurate in the US market.
For instance, we have several patents, including a so-called polymorphic patent that protects the specific crystal structure of the drug until 2042.
In addition to this, we have filed several more patent applications in the US, and we have similar protection in place or pending in the EU and other markets around the world. In practice, these strong patents provide protection against potential generic competition even after data exclusivity is expected to have expired, regardless of how long it lasts.
Let's now get a quick summary of the key events from the first quarter of 2025. Overall, we are continuing to strengthen our presence and visibility in academia and the medical profession by participating in a number of industry and scientific conferences. During the quarter, we participated in the Carnegie Healthcare Conference with Nordic Biotech and the JP Morgan Healthcare Conference. Additionally, during this period, we signed third-party supply contracts related to Phase 3 clinical studies, so we are good to go.
Now for this third quarter post-period, we published an article featuring the data from the Phase 2 study, demonstrating a high healing rate in patients with severe forms of erosive disease. We have held a scientific advisory meeting with NICE regarding the price and reimbursement for Linaprazan glurate. We had a very positive meeting with NICE. There is the British Institute for Health and Care Excellence. We also participated in the Disease Week in San Diego, where we presented, as I mentioned at the DW, data demonstrating Linaprazan glurate's strong acid effect along with the positive results from the optimized tablet formulation developed for the Phase 3 trials and future Cinclus commercialization.
As you already know, we have informed you about this earlier. And then we also participated in the 14th Expert Strategies in Endoscopy and Gastrointestinal Laparoscopic Disorders in Kansas City. All in all, we have had a busy and very productive start to 2025. If we're looking forward now and specifically considering the Phase 3 trial. Here we have some more details on our planned study starting up in the third quarter with the first patient being recruited. This is a European-US study where we have a significant number of sites in seven countries in Europe as well as in the US.
We intend to show that our drug candidate is more effective than Proton Pump Inhibitors, according to several study measures, including superior healing and superior symptom control. A positive outcome would make Linaprazan glurate unique in the market. We plan to start, as I already mentioned, patient recruitment. Now, in the third quarter of 2025.
And we anticipate topline results during next year.
And let's turn to the financials and to Maria. Please go ahead.